NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
Annovis Bio Promotes Cheng Fang to Chief Scientific Officer: Key FAQs
Annovis Bio promoted Dr. Cheng Fang to Chief Scientific Officer as it advances its lead drug buntanetap toward Phase 3 Alzheimer's data and NDA submission, aiming to halt neurodegeneration by targeting multiple toxic proteins.
Annovis Bio announced the promotion of Cheng Fang, Ph.D., to Chief Scientific Officer.
Fang will oversee scientific strategy and research operations across Annovis' Alzheimer's and Parkinson's programs, including translational science, clinical development, biomarker strategy, and regulatory interactions, as the company approaches key milestones for its lead drug buntanetap.
Annovis' lead drug candidate is buntanetap (formerly posiphen), an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins (APP, amyloid beta, tau, alpha-synuclein, TDP-43) via a specific RNA-targeting mechanism of action.
Annovis expects top-line data from its pivotal Phase 3 Alzheimer's disease study and a subsequent New Drug Application submission.
Cheng Fang joined Annovis in 2021 and most recently served as Senior Vice President of Research and Development before his promotion to CSO.
Annovis Bio is headquartered in Malvern, Pennsylvania.
Investors can find the latest news and updates in the company's newsroom at https://ibn.fm/ANVS.